Apogee Therapeutics shares surged 55.2% in pre-open trading today following reports that AbbVie is poised to formally unveil a $10.9 billion all-cash acquisition of the clinical-stage biotech. The reported price represents roughly a 60% premium to Apogee’s most recent closing price, and the Financial Times first reported the story on Friday, June 19, noting an official announcement could arrive as early as today if negotiations proceed without last-minute hurdles.
Analyst reaction and strategic fit
JPMorgan analysts published a note today reinforcing the upbeat market response, calling the potential deal a compelling strategic fit for AbbVie that would expand its immunology and atopic dermatitis assets. The research team pointed to the commercial prospects for Apogee’s lead program, zumilokibart (APG777), an extended half-life anti-IL-13 monoclonal antibody that recently met all primary and secondary endpoints in its Phase 2 Part B APEX trial. JPMorgan also noted that Phase 3 initiation in moderate-to-severe atopic dermatitis is anticipated in the second half of 2026.
Recent financing and institutional backing
Investors have had signals of institutional confidence in Apogee’s development pathway. In May 2026 the company announced a $1.3 billion non-dilutive financing collaboration with Blackstone Life Sciences, an arrangement that supports the pipeline without issuing new equity and that preceded the takeover reports.
Market context and deal significance
The broader market environment was favorable today, with the NASDAQ up 1.9% and the S&P 500 higher by 1.1%, a backdrop that tends to support risk assets and merger activity in the biotech sector. If completed, the acquisition would rank among the largest pharmaceutical M&A transactions of the year and would reflect an ongoing pattern of large-cap drugmakers acquiring clinical-stage biotech assets to refill pipelines facing long-term patent pressures.
Share movement and implied valuation
The confluence of an imminent acquisition announcement at a substantial premium, positive analyst commentary, and the company’s pipeline milestones pushed Apogee shares well above their previous 52-week high of $95.32 to trade at $140.31 in pre-market — a level that closely mirrors the valuation implied by the reported deal terms.
Taken together, these factors created a powerful set of catalysts that propelled Apogee stock higher in early trading while drawing attention to the strategic implications for AbbVie’s immunology pipeline.
Summary
Reports that AbbVie is nearing a $10.9 billion all-cash takeover of Apogee Therapeutics sent Apogee shares up 55.2% pre-market. JPMorgan described the proposed acquisition as a compelling strategic fit, citing the commercial potential of Apogee’s lead candidate APG777 and the expectation of Phase 3 initiation in the second half of 2026. The company’s May 2026 non-dilutive financing with Blackstone Life Sciences and a supportive market backdrop amplified investor enthusiasm.